Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach

David Ginn, David Kelsen, Mario Eisenberger, Robert Heelan, Gordon Magill

Research output: Contribution to journalArticle

Abstract

Twenty-five previously untreated patients with advanced adenocarcinoma of the upper gastrointestinal tract were treated with a combination of carboplatin and vinblastine. Two partial responses (duration three months and six months) were seen among 22 evaluable patients. Myelosuppression was the most common toxicity and was generally mild. The 8% response rate, (95% confidence interval 2 to 24%) observed in this study indicated that carboplatin-vinblastine has only modest activity in adenocarcinoma of the upper gastrointestinal tract. Although less toxic, this regimen appears to be less effective than previously reported cisplatin-containing regimens in adenocarcinoma of the upper GI tract.

Original languageEnglish (US)
Pages (from-to)321-324
Number of pages4
JournalInvestigational New Drugs
Volume8
Issue number3
DOIs
StatePublished - Aug 1990
Externally publishedYes

Fingerprint

Upper Gastrointestinal Tract
Vinblastine
Carboplatin
Stomach
Adenocarcinoma
Poisons
Cisplatin
Confidence Intervals

Keywords

  • carboplatin gastric cancer phase II

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach. / Ginn, David; Kelsen, David; Eisenberger, Mario; Heelan, Robert; Magill, Gordon.

In: Investigational New Drugs, Vol. 8, No. 3, 08.1990, p. 321-324.

Research output: Contribution to journalArticle

Ginn, David ; Kelsen, David ; Eisenberger, Mario ; Heelan, Robert ; Magill, Gordon. / Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach. In: Investigational New Drugs. 1990 ; Vol. 8, No. 3. pp. 321-324.
@article{25f54b27153e40f2b3b06de6f463114e,
title = "Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach",
abstract = "Twenty-five previously untreated patients with advanced adenocarcinoma of the upper gastrointestinal tract were treated with a combination of carboplatin and vinblastine. Two partial responses (duration three months and six months) were seen among 22 evaluable patients. Myelosuppression was the most common toxicity and was generally mild. The 8{\%} response rate, (95{\%} confidence interval 2 to 24{\%}) observed in this study indicated that carboplatin-vinblastine has only modest activity in adenocarcinoma of the upper gastrointestinal tract. Although less toxic, this regimen appears to be less effective than previously reported cisplatin-containing regimens in adenocarcinoma of the upper GI tract.",
keywords = "carboplatin gastric cancer phase II",
author = "David Ginn and David Kelsen and Mario Eisenberger and Robert Heelan and Gordon Magill",
year = "1990",
month = "8",
doi = "10.1007/BF00171847",
language = "English (US)",
volume = "8",
pages = "321--324",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach

AU - Ginn, David

AU - Kelsen, David

AU - Eisenberger, Mario

AU - Heelan, Robert

AU - Magill, Gordon

PY - 1990/8

Y1 - 1990/8

N2 - Twenty-five previously untreated patients with advanced adenocarcinoma of the upper gastrointestinal tract were treated with a combination of carboplatin and vinblastine. Two partial responses (duration three months and six months) were seen among 22 evaluable patients. Myelosuppression was the most common toxicity and was generally mild. The 8% response rate, (95% confidence interval 2 to 24%) observed in this study indicated that carboplatin-vinblastine has only modest activity in adenocarcinoma of the upper gastrointestinal tract. Although less toxic, this regimen appears to be less effective than previously reported cisplatin-containing regimens in adenocarcinoma of the upper GI tract.

AB - Twenty-five previously untreated patients with advanced adenocarcinoma of the upper gastrointestinal tract were treated with a combination of carboplatin and vinblastine. Two partial responses (duration three months and six months) were seen among 22 evaluable patients. Myelosuppression was the most common toxicity and was generally mild. The 8% response rate, (95% confidence interval 2 to 24%) observed in this study indicated that carboplatin-vinblastine has only modest activity in adenocarcinoma of the upper gastrointestinal tract. Although less toxic, this regimen appears to be less effective than previously reported cisplatin-containing regimens in adenocarcinoma of the upper GI tract.

KW - carboplatin gastric cancer phase II

UR - http://www.scopus.com/inward/record.url?scp=0025180319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025180319&partnerID=8YFLogxK

U2 - 10.1007/BF00171847

DO - 10.1007/BF00171847

M3 - Article

C2 - 2272772

AN - SCOPUS:0025180319

VL - 8

SP - 321

EP - 324

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -